

## **HUMAN RESEARCH ETHICS COMMITTEE - NORTHERN SECTOR**

Room G71 East Wing **Edmund Blacket Building** Prince of Wales Hospital RANDWICK NSW 2031

Tel: 02 9382 3587 Fax: 02 9382 2813 www.sesiahs.health.nsw.gov.au/Research Support/NHN/

29 April 2011

Dr Arun Krishnan Institute of Neurological Sciences Prince of Wales Hospital High St **RANDWICK NSW 2031** 

Dear Dr Krishnan

HREC ref no: 10/236

Project title: NEU-HORIZONS: The neuroprotection and therapeutic use of Riluzole for

the prevention of oxaliplatin neurotoxicity study.

Thank you for submitting the above application for ethical and scientific review. The application was first considered by the Human Research Ethics Committee (HREC) at a meeting on 22 February 2011 and subsequently on 5 April 2011at which further information was requested.

At that meeting the Committee requested that the investigator provide further information/clarification or modification delegating authority to approve the application to the Executive Officer upon receipt of a satisfactory response. The requested information and modifications were received with your correspondence dated 14 April 2011.

I am pleased to advise that ethical approval has been granted for this project to be conducted at the Prince of Wales Hospital.

The following documentation has been approved:

- NEAF, submission code AU/1/1942808
- Study protocol, version 2, dated 14 April 2011
- Participant Information Statement and Consent Form, version 3, dated 13 April 2011
- Participant Information Statement and Consent Form Tissue banking Genetic Repositories Australia, version 3, dated 14 April 2011

## Questionnaires:

- FACT/GOG-Ntx (4 item), not dated
- Total Neuropathy Score Clinical, not dated

## Case Report Forms:

- Baseline visit, version 1, dated 13 December 2010
- Regular visits, version 1, dated 13 December 2010

## Conditions of approval

- 1. This approval is valid for 5 years from the date of this letter.
- 2. Annual reports must be provided on the anniversary of approval.
- 3. A final report must be provided at the completion of the project.
- 4. Proposed changes to the research protocol, conduct of the research, or length of approval will be provided to the Committee.
- 5. The Principal Investigator will immediately report matters which might warrant review of ethical approval, including unforeseen events which might affect the ethical acceptability of the project and any complaints made by study participants.

**Optional** It is the responsibility of the sponsor or the principal (or co-ordinating) investigator of the project to register this study on a publicly available online registry (eg Australian New Zealand Clinical Trials Registry <a href="https://www.anzctr.org.au">www.anzctr.org.au</a>).

For NSW Public Health sites only: You are reminded that this letter constitutes ethical approval only. You must not commence this research project until you have submitted your Site Specific Assessment (SSA) to the Research Governance Officer of the appropriate institution and have received a letter of authorisation from the General Manager or Chief Executive of that institution.

Should you have any queries, please contact the Research Support Office on (02) 9382 3587. The HREC Terms of Reference, Standard Operating Procedures, membership and standard forms are available from the Research Support Office website: http://www.sesiahs.health.nsw.gov.au/Research Support/NHN/.

Please quote HREC ref no 10/236 in all correspondence.

We wish you every success in your research.

Deborah Adrian

ours sincerely

Executive Officer, Human Research Ethics Committee

THE HEROGONAMENTO STORMS IN CONTROL TO SERVICE TO SERVICE WITH THE SERVICE STORMS TO SERVICE TO SERVICE STORMS

TO STORM THE SERVICE S